A study of 216 women has identified a hormonal fingerprint that correctly distinguished endometriosis patients from healthy controls more than 95% of the time, researchers in Edinburgh report. The finding, published in the European Journal of Endocrinology, raises the prospect of a blood-based test that could slash the current UK average diagnosis delay of nine years, which today requires laparoscopic surgery. The team analysed blood from 159 women with confirmed endometriosis and 57 without, focusing on 11-oxygenated androgens produced by the adrenal glands. Those with the condition showed elevated levels of 11-ketotestosterone, a pattern the authors describe as a distinct signature that challenges the long-held view of endometriosis as solely an oestrogen-driven disorder.

The work, funded by Wellcome and the Medical Research Council, is now seeking industry partners to develop a diagnostic tool. While the results are promising, the charity Endometriosis UK stresses that larger trials are essential to validate the findings before any clinical rollout. The discovery arrives amid a broader re-examination of how hormonal interventions—both therapeutic and unregulated—affect women’s health. Across Europe and North America, clinicians are voicing concern over a wave of unlicensed peptides sold online for muscle growth, anti-ageing and fat loss. Substances such as ipamorelin and CJC-1295 artificially elevate growth hormone and IGF-1 for days, disrupting the finely tuned hypothalamic-pituitary-ovarian axis. Evidence suggests women face a 1.5 to 2 times higher risk of adverse drug reactions than men, partly because of stronger immune responses and hormonal fluctuations. One peptide, TB-500, a synthetic fragment of thymosin beta-4, has been detected in breast and lung cancer cells, a troubling signal given that lung cancer rates in younger American women have recently surpassed those of men.

Environmental factors, too, are reshaping the reproductive health picture. A separate study of nearly 400 men across four Spanish regions, presented at the European Society of Human Reproduction and Embryology meeting in London, found that semen quality in the north—Asturias—was almost double that of men in Madrid, with a mean total motile sperm count of 94.35 million versus 50.11 million. Lifestyle habits were similar across regions, leading the research team to attribute the gap to environmental exposures such as pollution. The findings echo earlier work in other European countries and China, reinforcing the view that local contaminants, not personal behaviour, drive regional fertility differences.

Rapid weight loss, whether through bariatric surgery or high-potency GLP-1 agonists, adds another layer of hormonal stress. Specialists in Brazil note that losing more than 1.5 kg per week sharply raises the risk of gallstones, as the liver floods bile with cholesterol and the gallbladder contracts less frequently. The risk is tied to the speed of loss rather than any single method. Taken together, these developments underscore a moment of both diagnostic promise and caution: a potential non-surgical test for endometriosis edges closer, but the parallel rise of unregulated hormonal products and the invisible hand of environmental pollutants demand rigorous, sex-specific scrutiny. The next milestones are larger validation trials for the endometriosis signature and, regulators hope, tighter controls on online peptide sales.